Skip to content

Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer

Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01441310
Acronym
SNNS
Enrollment
101
Registered
2011-09-27
Start date
2010-07-31
Completion date
2016-08-31
Last updated
2017-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

Gastric cancer, Sentinel node navigation surgery, Dual method, Recurrence

Brief summary

There are few reports on a dual dye and isotope approach using laparoscopy in gastric cancer sentinel node mapping. The aim of this study was to evaluate the feasibility of laparoscopic limited gastrectomy with sentinel basin(SB) dissection for gastric cancer using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections.

Detailed description

Prospective phase II clinical trials for sentinel node navigation surgery(SNNS) in early gastric cancer. Laparoscopic SNNS: 1. ICG and 99mTc-antimony sulfur colloid (ASC) submucosal injection under intraoperative endoscopy 2. Sentinel node basin identification and dissection 3. Sentinel nodes picking in back table 4. Frozen biopsy of sentinel nodes(hematoxylin and eosin staining and immunohistochemistry for cytokeratin) 5. If the sentinel node biopsy by frozen section is negative, limited gastrectomy will be performed or if positive, radical D2 gastrectomy will be performed. Sample size: 100 cases Study duration: 5 years( 2year enrollment, 3 year follow-up)

Interventions

PROCEDURELaparoscopic sentinel node navigation surgery

Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections

Sponsors

Seoul National University Bundang Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age 20-80 * Informed consent * No other malignancies * cT1N0 stage gastric cancers \< 4cm * no allergic history of isotope

Exclusion criteria

* Patients eligible for endoscopic submucosal dissection(ESD) with absolute indication

Design outcomes

Primary

MeasureTime frameDescription
3 Year disease free survivalPostoperative 3 yearRecurrence evaluation by eddoscopy, computed tomography and Positron emission tomography if needed.

Secondary

MeasureTime frameDescription
Sentinel node detection rate, occurrence of complication ,Qualtity of life and remnant stomach function evaluation.postoperative 1, 3, 6, 12 monthSentinel node detection rate and occurrence of complication of SNNS using dual method for gastric cancer were evaluated QoL questennaire and remnant stomach function were evaluated for the evaluation of patient's quality of life

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026